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Hepatic encephalopathy (HE) is a spectrum of 
neuropsychiatric abnormalities associated in patients 
with liver dysfunction and/or portosystemic shunting. 
It is one of the most serious complication of cirrhosis. 
HE is associated with increase hospitalization, 
increase in health cost, and mortality of cirrhosis 
patients. Approximately 30-45% of cirrhosis patients 
will develop HE and it is the most common cause of 
hospitalization in decompensated cirrhosis patients. 
Cirrhosis patients who had HE had 1-year survival 
probability of 42% and 3-year probability of 23%.1
HE comprises a complex, multifactorial, 
mechanisms resulting in functional impairment 
of neuronal cell. For many years, ammonia was 
considered as the main role of the pathogenesis of HE. 
However, many studies showed that blood ammonia 
levels may not correlate with the degree of HE 
suggesting more compounds were involved. In recent 
years, many agents emerge as a part of HE pathogenesis 
such as deposition manganese in the basal ganglia, 
benzodiazepine-like compounds, microbiota, aromatic 
amino acids, and also inflammatory cytokines.1
Many evidences showed that inflammation plays 
important role in the development of HE. Astrocytes 
and microglia are capable to produce proinflammatory 
cytokines as a response to inflammatory state in 
cirrhosis patients.2 These cytokines will increase 
blood-brain barrier permeability for ammonia and its 
passage into astrocytes.3 It has been long documented 
that the levels of pro-inflammatory cytokines including 
tumor necrosis factor-α (TNF-α) and interleukins (ILs) 
were increase in decompensated cirrhotic patients.4 In 
1995, Izumi et al had shown that interleukin (IL)-6 was 
correlated with fulminant hepatic failure and chronic 
HE.5 Since then, multiple interleukins were identified 
to be associated with HE including IL-18.6
IL-18 is a proinflammatory cytokine, previously 
describe as interferon γ-inducing factor, involved 
in activation and differentiation of various T cell 
populations.7 IL-18 show proinflammatory properties 
such as increase in cell-adhesion molecules, nitric 
oxide synthesis, and chemokine production.8 Other 
than induce the inflammatory state, IL-18 may induce 
HE by disturbed intestinal permeability and mucus 
production by goblet cells resulted in dysbiosis and 
increase of plasma endotoxin.7,10 
Recent study by Anton et al showed that mean 
serum of IL-18 levels were higher in the cirrhosis 
patients compared to healthy controls (688.5 ± 674.3 
pg/mL vs. 163.9 ± 100 pg/mL; p = 0.01). In this 
study, IL-18 was significantly correlated with HE (r = 
0.85; p < 0.05). More importantly, IL-18 levels were 
significantly different between the severity grade of 
HE.11 These evidences show possibilities to utilize 
IL-18 for diagnosis and management HE in the future.
REFERENCES
1. Elwir S, Rahimi RS. Hepatic encephalopathy: an update on 
the pathophysiology and therapeutic options. J Clin Transl 
Hepatol 2017;5:142–51.
2. Haussinger D, Schiliess F. Astrocyte swelling and protein 
tyrosine nitration in hepatic encephalopathy. Neurochem Int 
2005;47:64-70.
3. DeVries HE, Bloom-Roosemalen MC, Van OM, DeBoer 
AG, Van Berkel TJ, Breimer DD, et al. The influence of 
cytokines on the integrity od the blood-brain barrier in vitro. 
J Neuroimmunol 1996;64:37-43.
4. Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier 
G, et al. Serum levels of cytokines in chronic liver diseases. 
Gastroenterology 1992;103:264-74.
5. Izumi S, Hughes RD, Langley PG, Pernambuco JR, 
Williams R. Acute phase response after liver transplantation 
for fulminant hepatic failure and cirrhosis. Transpl Int 
1995;8:340–5.
6. Mueser UF, Schimdt OI, Oberholzer A, Bu¨hrer C, 
Stahel PF. IL-18: a key player in neuroinflammation and 
neurodegeneration? Elsevier 2005;28:487-93.
7. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. 
Interleukin-18 regulates both Th1 and Th2 responses. Annu 
Rev Immunol 2001;19:423-74.
8. Kaplanski G. Interleukin-18: biological properties and roles 
in disease pathogenesis. Immunol Rev 2018;281:138–53.
9. Jain L, Sharma BC, Sharma P, Srivastava S, Agrawal A, 
Sarin SK. Serum endotoxin and inflammatory mediators in 
patients with cirrhosis and hepatic encephalopathy. Elsevier 
2012;44:1027-31.
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy66
Andri Sanityoso Sulaiman
10. Hanck C, Manigold T, Böcker U, Kurimoto M, Kölbel 
C, Singer M, et al. Gene expression of Interleukin-18 in 
unstimulated peripheral blood mononuclear cells of patients 
with alcoholic cirrhosis. Gut 2001;49:106-11.
11. Komala A, Mustika S, Pratomo B. Overview of serum 
Interleukin-18 (IL-18) levels in liver cirrhosis patients 
and their correlation to hepatic encephalopathy. Indones J 
Gastroenterol Hepatol Dig Endosc 2018;19:67-73.
